Back to Journals » OncoTargets and Therapy » Volume 12

Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report

Authors Zhou L, Ren Y, Wang X, Miao D, Lizaso A, Li H, Han-Zhang H, Qian J, Yang H

Received 25 February 2019

Accepted for publication 20 June 2019

Published 4 July 2019 Volume 2019:12 Pages 5305—5309

DOI https://doi.org/10.2147/OTT.S206732

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jyoti Bajaj

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche


Li Zhou,1,* Yifeng Ren,2,* Xia Wang,1 Dongliu Miao,3 Analyn Lizaso,4 Haiyan Li,4 Han Han-Zhang,4 Jun Qian,1 Hui Yang1

1Oncology Department, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China; 2Hepatobiliary and Pancreatic Surgery Department, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China; 3Interventional Department, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, People’s Republic of China; 4Burning Rock Biotech, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: Afatinib has improved the prognosis of epidermal growth factor receptor-positive advanced non-small cell lung cancer and has been explored in the treatment of human epidermal growth factor receptor 2 (HER2)-amplified breast cancer. However, its clinical efficacy in HER2-amplified endometrial cancer has not been reported. Herein, we present the clinical benefit of afatinib in a case of stage IIIC endometrioid adenocarcinoma refractory to multiple lines of chemotherapy and eventually developed pulmonary, abdominal and pelvic metastasis. Upon referral to our clinic, capture-based targeted sequencing was performed on both blood and tumor samples and revealed HER2 amplification. The patient was administered with afatinib and achieved partial response (PR) after two months of treatment, reflected by a significant reduction in pulmonary lesions and serum levels of tumor markers including carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, 125, 15-3 and cytokeratin 19 fragment antigen 21-1 (CY211). The patient passed away after 3 months of afatinib treatment due to suspected complications of severe intestinal obstruction. Our report demonstrates the efficacy of afatinib in a heavily pre-treated HER2-amplified endometrial cancer patient with multi-organ metastasis. This case also highlights the need to include comprehensive mutational profiling in the standard management of endometrial cancer patients for treatment guidance.

Keywords: afatinib, HER2-amplification, HER-2 positive, endometrial cancer, case report, lung metastasis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]